Cns Pharmaceuticals, Inc. (CNSP) — 10-Q Filings

10-Q Filings (6)

• CNSP Narrows Q3 Loss Amidst Aggressive Equity Raises — Nov 14, 2025 Risk: high
  CNS Pharmaceuticals, Inc. (CNSP) reported a net loss of $9,894,762 for the nine months ended September 30, 2025, an improvement from the $11,681,435 net loss in
• CNS Pharma's Cash Boosted by Offerings Amid Rising R&D, Mounting Losses — Aug 14, 2025 Risk: high
  CNS Pharmaceuticals, Inc. reported a net loss of $6,676,281 for the six months ended June 30, 2025, an increase from the $6,075,501 net loss in the same period
• CNS Pharmaceuticals Files Q1 2025 10-Q — May 15, 2025 Risk: medium
  CNS Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its business o
• CNS Pharmaceuticals Files Q3 2024 10-Q — Nov 14, 2024 Risk: medium
  CNS Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results for the third quarter and the first ni
• CNS Pharmaceuticals Files Q2 2024 10-Q — Aug 14, 2024 Risk: medium
  CNS Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results for the second quarter and the first ha
• CNS Pharmaceuticals Files 10-Q for Period Ending March 31, 2024 — May 15, 2024 Risk: medium
  CNS Pharmaceuticals, Inc. (CNSP) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. CNS Pharmaceuticals, Inc. filed a 10-Q for the quarter ended Marc

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX